SEC Tracker
Get the app

Merck MRK

Merck reports $5.07 billion net income for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $18.09 billion for the three months ended Sep 30, 2026
  2. Net income of $5.07 billion for the three months ended Sep 30, 2026
  3. Diluted EPS of $2.04 for the three months ended Sep 30, 2026
  4. Cash and equivalents of $9.55 billion at Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Merck files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  2. Amgen AMGN public float $150.1B, Jun 30, 2025
  3. Pfizer PFE public float $138.0B, Jun 29, 2025
  4. AbbVie ABBV public float $325.1B, Jun 30, 2025
  5. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025